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Abstract
Background and Aims: Intestinal epithelial cells [IECs] secrete cytokines that recruit immune cells 
to the mucosa and regulate immune responses that drive inflammation in inflammatory bowel 
disease [IBD]. However, experiments in patient-derived IEC models are still scarce. Here, we aimed 
to investigate how innate immunity and IEC-specific pattern recognition receptor [PRR] signalling 
can be involved in an enhanced type I interferon [IFN] gene signature observed in colon epithelium 
of patients with active IBD, with a special focus on secreted ubiquitin-like protein ISG15.
Methods: Gene and protein expression in whole mucosa biopsies and in microdissected human 
colonic epithelial lining, in HT29 human intestinal epithelial cells and primary 3D colonoids 
treated with PRR-ligands and cytokines, were detected by transcriptomics, in situ hybridisation, 
immunohistochemistry, western blots, and enzyme-linked immunosorbent assay [ELISA]. Effects 
of IEC-secreted cytokines were examined in human peripheral blood mononuclear cells [PBMCs] 
by multiplex chemokine profiling and ELISA.
Results: The type I  IFN gene signature in human mucosal biopsies was mimicked in Toll-
like receptor TLR3 and to some extent tumour necrosis factor [TNF]-treated human IECs. In 
intestinal biopsies, ISG15 expression correlated with expression of the newly identified receptor 
for extracellular ISG15, LFA-1 integrin. ISG15 was expressed and secreted from HT29 cells and 
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experiments using PBMCs, we show that ISG15 releases IBD-relevant proinflammatory cytokines 
such as CXCL1, CXCL5, CXCL8, CCL20, IL1, IL6, TNF, and IFNγ.
Conclusions: ISG15 is secreted from primary IECs upon extracellular stimulation, and mucosal 
ISG15 emerges as an intriguing candidate for immunotherapy in IBD.
Key Words:  Human intestinal organoids; innate immunity; ISG15
1. Introduction
Recent evidence suggests that the intestinal epithelium contributes 
to the development and perpetuation of inflammation in the inflam-
matory bowel diseases [IBD], ulcerative colitis [UC], and Crohn’s 
disease [CD].1,2 In addition to having barrier functions, intestinal 
epithelial cells [IECs] act as both sensors for pathogen- or damage-
associated molecular patterns [PAMPs or DAMPS] and as regulators 
of immune cells.3,4 Binding of exogenous PAMPs or endogenous 
DAMPS to pattern recognition receptors [PRRs], such as Toll-like re-
ceptors [TLRs], initiate a number of intracellular signalling cascades 
via, for example, the transcription factor complexes nuclear factor 
kappa-light-chain-enhancer of activated B cells [NF-κB], mitogen-
activated protein kinases [MAPKs], or interferon regulatory factors 
[IRFs]. Activation of NF-κB and MAPKs in IECs induces secretion 
of interleukins and chemokines, whereas IRFs are more involved in 
stimulation of interferon [IFN] production and induction of IFN-
stimulated genes [ISGs].5,6 IFNs are classified into three types: type 
I [13 subtypes of IFNα, single members of IFNβ κ, ω, ε, δ, and τ], 
type II [IFNγ], and type III [IFNλ1, IFNλ2, and IFNλ3].7
Upon external stimuli, IECs have potential to secrete chemokines 
that can both recruit immune cells and directly induce secretion of 
inflammatory cytokines that augment and prolong inflammatory re-
sponses. For example, C-X-C motif chemokine ligand 8 [CXCL8], 
secreted from IECs and immune cells, is considered to be a major 
chemotactic factor which can attract, for example, CXCR1[+]
CXCR2[+]IL-23-producing neutrophils that infiltrate and accumu-
late in inflamed colon tissue.8 Previous work from our group has 
shown that extracellular stimulation of TLR3 can mediate release of 
immunomodulatory C-X-C motif chemokine ligand 10 [CXCL10]9 
and chemokine [C-C motif] ligand 20 [CCL20]10 from colonic epi-
thelial cells. A recent study showed that the human colonic epithelial 
cell line NCM460 transfected with the TLR3 ligand poly[I:C] re-
leased exosomes containing canonical type I IFN-induced antiviral 
ISGs such as ubiquitin-like protein ISG1511. To our knowledge, no 
study regarding release of ISG15 from primary human IECs upon 
external stimuli has been reported.
ISG15 exists in three forms: conjugated to proteins [ISGylation], 
unconjugated intracellular, and secreted free forms.12 There appears 
to be functional diversity between species,13,14 and in humans sev-
eral immunomodulatory functions of secreted free ISG15 have been 
postulated, including chemotaxis of neutrophils,15 recruitment of 
IL1β-producing CD8α+ dendritic cells,16 and release of IFNγ14,17,18 
and IL1019,20 from lymphocytes. Recently, Swaim et al.19 showed that 
extracellular ISG15 regulates IFNγ and IL10 secretion from the natural 
killer [NK] cell line NK-92 through the leukocyte function-associated 
antigen-1 [LFA-1] integrin receptor. The LFA-1 has two subunits, 
CD11a[αL integrin] and CD18[β2 integrin], encoded by the ITGAL 
and ITGB2 genes, respectively. Swaim et  al.19 suggest that direct 
binding of ISG15 to CD11a signals and activates SRC family kinases 
[SFKs], leading to secretion of IFNγ and IL10. In their model, IL12 
drives cytokine expression and ISG15 enhances cytokine secretion.
IEC-derived cytokines that augment and prolong inflammatory 
responses during active IBD are potential targets for immunotherapy. 
Gene lists in omics studies from our group21 and others22–24 show en-
hanced expression of ISG15 mRNA in active IBD and in experimental 
murine colitis. Even though ISG15 may boost mucosal immune ac-
tivity, ISG15 has not been investigated in the context of primary co-
lonic epithelial cells and IBD. Here, we show increased expression of 
canonical type I IFN-induced ISGs in IECs during active inflammation. 
We study how IEC-specific PRR-signalling can contribute to the type 
I IFN signature found, and demonstrate that extracellular ISG15 has 
cytokine-like activities that can modulate immune functions in IBD.
2.  Methods
2.1. Ethics
The study was approved by the Regional Committee for Medical 
and Health Research Ethics [reference numbers 5.2007.910 and 
2013/212/REKmidt] and was registered in the Clinical Trials 
Protocol Registration System [identifier NCT00516776]. All subjects 
included in the study gave informed written consent.
2.2. Clinical material
Patients admitted to St Olav’s University Hospital, Trondheim, 
Norway, for colonoscopy were included after informed consent. 
They were diagnosed with UC or CD or underwent colonoscopy 
due to gastrointestinal symptoms with no significant pathology 
being found. Patients using immunomodulants such as azathioprine 
or tumour necrosis factor ]TNF]-blockers were excluded. Colonic 
pinch biopsies [Sample set I] and peripheral blood mononuclear cells 
[PBMCs] [Sample set II], were collected as described previously.21,25
2.2.1. Sample set I
The colonic pinch biopsies were from a previously described 
cross-sectional study biobank21 including clinical information, 
blood fractions, and tissue samples. Haematoxylin and eosin-stained 
sections of all biopsies were examined by an experienced pathologist 
and classified into normal, inactive, or active inflammation.
2.2.2. Sample set II
PBMCs from non-IBD controls [n = 7], inactive CD [CDi, n = 8], 
and inactive UC [UCi, n = 9], and from active CD [CDa, n = 8] and 
active UC [UCa, n  =  7], were randomly selected from Sample set 
I, as described.25 PBMCs isolated from buffy coat from six healthy 
blood donors at the Department of Immunology and Transfusion 
Medicine, St Olav’s University Hospital, were included for add-
itional functional assays, as described below.
2.3. PRR-ligands, cytokines, neutralising antibodies, 
and inhibitors used in the stimulation experiments
The PRR-ligands used were: the lipopeptide Pam3CysSK4 [P3C] 
[TLR2/1] [300 ng/mL] [#L2000, EMC microcollections], Lipomannan 
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[LM] [TLR2/6] [30 ng/mL] [#tlrl-hkmt-1], polyinosinic:polycytidylic 
acid (poly[I:C) [TLR3] [5–70 µg/mL] [#tlrl-pic], lipopolysaccharide 
[LPS] [TLR4] [100 ng/mL] [#tlrl-peklps], Flagellin [TLR5] [100 ng/
mL] [#tlrl-stfla], the antiviral compound R848 [TLR7/8] [100 ng/
mL] [#tlrl-r848], the peptidoglycan component muramyl dipeptide 
[MDP] [NOD2] [1  µg/mL] [#tlrl-mdp], all from InvivoGen, and 
unmethylated CpG dinucleotides [TLR9] [10  μM] [# 1712649, 
TibMolBiol].
Recombinant cytokines used were: IL-10 [100 ng/mL] [#200–10], 
IL-1β [100 ng/mL] [#200-01B], TNF [100–200 ng/mL] [#300-01A], 
and IFNβ [0.1–10 ng/ml] [#300-02BC] [all from PeproTech], IL12 
[20 ng/mL] [#219-IL, R&D], and ISG15 [500 ng/ml] [#12729HNAE, 
Thermo Fisher Scientific]. JAK-inhibitors used were: filgotinib 
[10  µM] [GLPG0634] [#S7605, Selleckchem.com] and ruxolitinib 
[10 µM] [#tlrl-rux, InvivoGen]. Neutralising antibodies used were: 
rabbit anti-human IFN-β [2.5 µg/ml] [#500-P32B, PeproTech] and 
isotype control rabbit IgG [2.5 µg/ml] [#X0903, Dako Cytomation]. 
For details, see Supplementary Table 1, available as Supplementary 
data at ECCO-JCC online.
2.4.  Experiments in HT29 human intestinal 
epithelial cells
HT29 cells [#HTB-38, ATCC, Manassas, VA, USA] were cultured at 
37°C, 5% CO2 in RPMI supplemented with 10% fetal bovine serum, 
2 mM glutamine and 0.05% gentamicin. Stimulation experiments 
were performed on confluent cells in 12-well plates. The day before 
stimulation, the cells were incubated overnight in serum-depleted 
medium. Medium was then removed and fresh medium with 2–10% 
fetal bovine serum and PRR-ligands and cytokines were added for 
the time indicated in the different experiments.
2.5.  Experiments in human 3D colonoids
Human 3D colonoid cultures were established from colonic pinch 
biopsies taken from three non-IBD healthy controls, using an op-
timised protocol from Mahe et al.26 based on Jung et al.27 Briefly, 
isolated crypt pellets were resuspended in basement membrane ma-
trix [Corning® Matrigel GFR, #734–1101, Corning, NY, USA], and 
50  µl of crypt suspension was added to each well in pre-warmed 
24-well plates. The crypts were incubated with complete medium, 
composed of 50% Wnt-3A conditioned medium [#ATCC® CRL-
2647™] and 50% Advanced DMEM/F12 [#12634028, Thermo 
Fisher Scientific, Bremen, Germany], containing recombinant human 
r-spondin [1 µg/ml] [#120–38], recombinant human noggin [0.1 µg/
ml] [#120-10C] from PeproTech [Rocky Hill, NJ, USA], and other 
factors critical for stem cell growth, as described.26 For establishment 
of colonoids from crypts, the complete medium was supplemented 
by the GSK3 inhibitor [Wnt-activator] CHIR99021 [0.86  µg/ml] 
[#72052], and thiazovivin [0.778 µg/ml] [#72252], an inhibitor of 
rho-associated coiled-coil containing protein kinase [ROCK], both 
from STEMCELL Technologies.
Undifferentiated cultured colonoids were passaged and ex-
panded every 7 to 10 days after plating, or frozen for biobanking, 
as described.26 Before experiments, approximately 8000 cells 
were cultured in basement membrane matrix [Corning® Matrigel 
GFR] and grown in complete medium, with the selective ROCK-
inhibitor Y-27632 [3.203µg/ml] [#1254, Bio-Techne] added for the 
first 3 days. Medium was changed every 2–3 days, and the undif-
ferentiated colonoid cultures were differentiated at Day 7 by re-
ducing the Wnt-3A-conditioned medium concentration from 50% 
to 5%, removing nicotinamide [1221.2  µg/ml] [#N3376-100G, 
MerckMillipore] and the MAPK inhibitor SB202190 [3.314 µg/ml] 
[#S7067, Sigma-Aldrich, Missouri, USA], and adding the pan-notch 
inhibitor DAPT [4.324 µg/ml] [#2634, Bio-Techne] to the medium. 
Experiments were performed after 4–5 days of differentiation. A-83-
01 [0.211 mg/ml] [#SML0788, Sigma-Aldrich, Missouri, USA], an 
inhibitor of TGFβ type I  activin receptor-like kinase [ALK5] was 
removed during stimulation experiments.
2.6.  Experiments in PBMCs
Human PBMCs [Sample set II] were prepared and thawed as previ-
ously described.25 For stimulation experiments, recombinant human 
ISG15 [500  ng/mL] and/or recombinant human IL12 [20  ng/mL] 
were added for 48 h before conditioned medium was harvested and 
stored at -80°C.
2.6.1. Flow cytometry
PBMC subpopulations in 35 samples [Sample set II] had previously 
been identified by flow cytometry analysis,25 and the data were used 
for correlation analyses in the present study. Detailed description of 
antibody staining and compensation controls are given in Skovdahl 
et al.25 Flow cytometry was performed on a BD FACS Canto II flow 
cytometer with FACS Diva software from BD Bioscience [10  000 
events per sample] and samples were analysed using FlowJo v10 
software from Flow Jo, LLC.
2.7.  Enzyme-linked immunosorbent assay and 
multiplex chemokine profiling
CircuLex Human ISG15 ELISA Kit [#CY-8085, Nordic Biosite]; 
human IFNγ [#88-7316-86, Invitrogen, Thermo Fisher Scientific, 
Bremen, Germany]; TNF [#DY210], CXCL10 [#DY266], CCL20 
[#DY360] and CXCL8 [#DY208]; all [R&D]; were used ac-
cording to the manufacturers’ protocol. Cytokines in conditioned 
medium from stimulated PBMCs were detected and analysed by 
Bio-Plex Pro™ Human Chemokine Panel, 40-Plex [#171ak99mr2, 
Bio-Rad laboratories] according to the manufacturer’s protocol. 
The Limulus Amebocyte Lysate [LAL]-assay [#50-647U, LONZA 
Walkersville, MD USA, QCL-100TM] was performed according to 
the manufacturer’s instructions to confirm that the levels of endo-
toxin were well below 1 EU [<0.1 ng] per µg protein, as stated by the 
suppliers of both recombinant IL12 and ISG15. Nevertheless, since 
even 0.02 ng/ml LPS has been shown to significantly stimulate small 
amounts of cytokine production,28 we defined cytokine release to be 
modulated by ISG15 only if the enhanced cytokine concentration 
in conditioned medium was above 1000 pg/ml compared with un-
treated control in the multiplex assay.
2.8.  RNA extraction and gene expression analysis
The following kits were used for RNA extraction, according to 
the manufacturers’ protocol: Ambion mirVana mRNA isolation 
kit [Applied Biosystems] [human biopsies], RNeasy micro plus 
[#74034, Qiagen] [microdissected epithelial monolayer], RNeasy 
Mini kit [#74106, Qiagen] [HT29 cells and colonoids], and RNeasy 
mini kit and QiaShredder columns [#ID:79654, Qiagen] [PBMCs].
Microarray gene expression analysis of the human colonic biop-
sies [Sample set I] has previously been described.21 A subset [n = 29] 
with inflamed, active IBD [n = 12:5 CDa + 7 UCa], uninflamed IBD 
[n = 11:5 CDi + 6 UCi], and non-IBD controls [n = 6] from Sample 
set I was used for RNA sequencing of laser capture microdissected 
[LCM] epithelial monolayer. The microdissection was performed 
on an MMI CellCut LCM microscope [MMI CellCut on Olympus 
IX71]. Samples were mounted in Tissue-Tek O.C.T compound 
embedding medium [Sakura Finetek, Europe]. After a period of 
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30 min in the cryotome [Leica CM3050 S, Leica], 10-µm cryosections 
were cut and mounted on a pre-chilled LCM membrane slide. The 
slide was briefly exposed to room temperature to let sections ad-
here and was placed in chilled 100% EtOH [30 s]. Before LCM, 
samples were stained and de-humidified with H2O  +  ProtectRNA 
RNAse inhibitor [#R7397, Sigma-Aldrich, Missouri, USA] [2 × 5 s], 
Histogene staining solution [# KIT0401, Life Technologies] [30 s], 
100% EtOH [3 × 30 s], and xylene [5 min], and left for desicca-
tion in a vacuum chamber containing silica gel [30 min]. Following 
the pre-processing steps, an area corresponding to approximately 
10 000 epithelial cells [1 mm2] underwent LCM, was immediately 
lysed by adding 300 µL lysis buffer, and was stored at -80°C. The 
RNA sequencing [RNASeq] was done on libraries prepared using 
Illumina TruSeq RNA access library kit [Illumina, Inc., San Diego, 
CA, USA] according to the manufacturer’s protocol.
Microarray gene expression analysis of HT29 cells was per-
formed using Illumina human HT-12 expression BeadChips 
[Illumina, Inc., San Diego, CA, USA] on an Illumina BeadStation, 
following standard protocols.
For RNASeq of human 3D colonoids, RNASeq libraries were 
generated using SENSE total RNASeq library prep kit [with 
RiboCop rRNA depletion] according to manufacturer’s instruc-
tions [Lexogen GmbH]. Single-read sequencing was performed for 
75 cycles on a NextSeq 500 instrument [Illumina]. Base calling was 
done on the NS500 instrument by RTA 2.4.6. FASTQ files were gen-
erated using bcl2fastq2 Conversion Software v2.17 [Illumina, Inc., 
San Diego, CA, USA].
For real-time quantitative polymerase chain reaction [RT-qPCR] 
of ITGAL and ITGB2 expression in PBMCs [Sample set II], RNA ex-
traction and reverse transcription were done as previously desrcibed.25 
cDNA was analysed for LFA-1 subunits ITGAL and ITGB2 transcripts 
by quantitative real-time PCR using Taqman probes [ITGAL: probe 
ID Hs_00158218_m1; ITGB2: probe ID Hs_00164957_m1] with the 
reference genes beta actin [ACTB: probe ID Hs01060665_g1], TATA 
box binding protein [TBP: probe ID Hs00427620_m1] and eukary-
otic 18S rRNA [18S: probe ID Hs99999901_s1] [Applied Biosystems]. 
PerfeCTa assay with PerfeCTa qPCR FastMix [Quantabio], and 
StepOnePlusTM Real-Time PCR System and StepOneTM software v2.1 
[Applied Biosystems] were used for all PCR procedures.
2.9.  Bioinformatics and Gene set enrichment 
analysis
In general, expression analysis was done in the R software environ-
ment for statistical computing.29 Analysis of the microarray gene ex-
pression data from Sample set I has been previously described.21 For 
gene expression analysis in colonic pinch biopsies, LCM epithelial 
monolayer, and colonoids, differential expression between groups 
was identified using LIMMA linear models with least squares re-
gression and empirical Bayes moderated t statistics.30 Temporal 
gene expressions in treated and untreated HT29 cells were identi-
fied using LIMMA linear models with least squares regression and 
empirical Bayes moderated nested F statistics30; p-values were ad-
justed for multiple comparisons using the Benjamini-Hochberg false-
discovery rate correction [FDR]. Enrichment analyses were done by 
MetaCoreTM version 6.34 build 69200.
2.10.  Western blotting
Cells were washed twice in ice-cold PBS before they were lysed for 
2 h on ice in lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
5 mM EDTA, 1% NP-40, 1 mM DTT, 1 x Complete® EDTA-free 
protease inhibitor, and 1 x phosphatase inhibitor cocktail I  and 
III, respectively [Sigma-Aldrich, Missouri, USA]. Protein lysate was 
obtained by centrifugation at 14 000 × g for 20 min at 4°C, and pro-
tein concentration was measured using the Bradford protein assay 
[Bio-Rad]. Conditioned medium from HT29 cells was concentrated 
from 500 μL to 50 μL using Amicon® ultra-0.5 centrifugal filter de-
vices, 10 000 NMWL [Millipore], according to the manufacturer’s 
recommendations.
Samples were denatured in 1  × NuPage LDS sample buffer 
supplemented with 40  mM DTT for 10  min at 70°C before they 
were separated on 4–12% NuPage Bis-Tris gels [Invitrogen] and 
electroblotted onto Immobilon PVDF membranes [Millipore]. The 
membranes were blocked using 5% BSA in PBS/0.01% Tween 
20 [PBS-T] and incubated with primary antibodies as listed in 
Supplementary Table 2, available as Supplementary data at ECCO-
JCC online. For visualisation, the blots were incubated with IRDye 
800CW goat anti-mouse IgG [1:20 000, LI-COR, LCR-926–32210] 
or with horseradish peroxidase [HRP] conjugated swine anti-rabbit 
IgG and HRP-conjugated rabbit anti-mouse IgG [both 1:5000, Dako 
Cytomation] developed with Super Signal West Femto substrate 
[Pierce]. Images were obtained with LI‐COR Odyssey Fc and ana-
lysed using Image Studio Software [LI‐COR].
2.11.  Immunohistochemistry and in situ 
hybridisation of human biopsies and colonoids
The human colonic biopsies were fixed in 10% buffered formalin 
for 3–6 days before embedding in paraffin. For fixation of human 
colonoids, the Matrigel was depolymerised using Cell Recovery 
Solution, and the colonoids were washed with PBS and centrifuged 
[500 × g] three times. The colonoid pellets were either resuspended 
in 50 µl Richard-Allan Scientific™ HistoGel™ Specimen Processing 
Gel [# HG-4000–012, Thermo Fisher Scientific] or small amounts 
[1:5  µl] of plasma and thrombin that was allowed to coagulate 
before the pellets were fixed in formalin for 48  h and embedded 
in paraffin. The formalin-fixed, paraffin-embedded [FFPE] biop-
sies or colonoids were cut into 4-µm sections before standard pre-
treatments and staining with haematoxylin and eosin.
FFPE sections were processed through standard 
de-paraffinisation and quenching of endogenous peroxidase before 
immunohistochemistry [IHC]. Antigen retrieval was achieved by 
15 min boiling in citrate buffer [pH 6.0] [a-ISG15, E-cadherin] or 
Tris-EDTA buffer [pH 9.0] [a-pSTAT, a-CD11a, a-FABP1, a-MUC2, 
a-CgA] using a commercial microwave. All sections were incubated 
overnight at 4°C with primary antibodies diluted in PBS with 0.25% 
Triton-X and 0.25% BSA. Primary antibodies and dilutions are 
listed in Supplementary Table 2. Immunoreactions were visualised 
using the rabbit/mouse EnVision-HRP/DAB+ kit [#K5007, Dako] 
and counterstaining with haematoxylin. Negative controls were 
omission of primary antibody and similar concentration of identical 
non-immunised IgG.
In situ hybridisation [ISH] was performed with the RNAscope 
2.5 HD Reagent Kit [Brown] for FFPE tissue [#322300] and human 
ISG15 probe [#467741] [Advanced Cell Diagnostics, Inc.,] according 
to the manufacturer’s instructions. Images were captured using Nikon 
E400 microscope, DS-Fil U2 camera, and NIS-Elements BR imaging 
software [Nikon]. Further processing was done using Fiji.31
2.12.  Statistical analyses
Except for the global gene expression analyses described in Methods 
section 2.9, statistical analyses were performed in GraphPad Prism 
8.0 [GraphPad Software, Inc., San Diego, CA, USA]. For numerical 
values and log2 transformed data, differences between groups were 
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evaluated by analysis of variance [ANOVA] with multiple comparison 
tests, as indicated in the figure legends. Briefly, Dunnett’s test was 
used when comparing multiple treatments versus a control, Tukey 
test when comparing every treatment with every other treatment, and 
Šídák test when selected groups were compared. Pearson’s correlation 
coefficient or Spearman rank correlation was used to examine correl-
ations; p <0.05 was considered significant for all analysis.
2.13.  Data availability
Transcriptome analysis of Sample set I  is available at Array 
Express E-MTAB-184. Selected gene expression data are shown in 
Supplementary Files 1–4, available as Supplementary data at ECCO-
JCC online. The authors declare that all data supporting the results 
presented in this study are available within the article and supple-
mentary material or are available from the corresponding author 
upon reasonable request.
3.  Results
3.1.  Expression of type I IFN signature genes is 
increased in IECs from patients with active IBD
Exploration of an in-house microarray gene expression dataset on 
well-characterised and controlled colon pinch biopsies from non-
IBD controls [n  =  20] and inactive and active UC [n  =  81] and 
CD [n  =  26]21 revealed that several canonical ISGs were signifi-
cantly upregulated in mucosa during active disease [Figure  1 and 
Supplementary File 1]. We could not detect upregulation of IFNα or 
IFNβ mRNAs in mucosa from IBD patients compared with non-IBD 
controls [Supplementary File 1]. However, significantly enhanced ex-
pression of signal transducer and activator of transcription 1 and 2 
[STAT1, STAT2] and IFN-regulatory factors 1 and 9 [IRF1, IRF9] in 
both active UC [n = 37] and CD [n = 7] indicated induction of type 
I IFN signalling pathways during active disease. Signalling through 
interferon α/β receptor [IFNAR] activates Janus kinase 1 [JAK1] and 
tyrosine kinase 2 [TYK2] which phosphorylate STAT1 and STAT2. 
STAT1/STAT2 heterodimer can interact with IRF9 to form IFN-
stimulated gene factor 3 [ISGF3] which binds to IFN-stimulated 
response DNA element [ISRE] and induces transcription of ISGs.32 
The upregulated ISGs shown in Figure 1 have been reported to be 
strongly enriched for the ISGF3-binding ISRE motif.33,34
To examine whether the ISGs were produced by IECs, we ana-
lysed an in-house RNASeq-dataset showing gene expression in laser-
captured, microdissected, epithelial monolayer from inflamed, active 
IBD [n = 12] versus uninflamed IBD [n = 11] and non-IBD controls 
[n = 6]. Several type I  IFN genes [IFNAR2, STAT1, IRF1, ISG15, 
ISG20, IFI16, IFIT3, IFITM1, IFITM2, IFITM3, OAS2, OAS3, and 
USP18] were upregulated also in the separated IECs during active 
IBD [Figure 2A and Supplementary File 2].
Since ISG15 in particular has potential to boost IBD-relevant 
immune activities,12,19 we proceeded to examine localisation of 
pSTAT1, ISG15 proteins, and the ISG15 binding receptor unit 
CD11a [ITGAL]19 in colon mucosa biopsies from non-IBD con-
trols and active IBD by IHC [Figure 2B–D]. Although we observed 
increased levels of pSTAT1 and ISG15 in the colonic epithelium 
monolayer from active IBD compared with non-IBD controls, the 
newly identified receptor subunit for extracellular ISG15, CD11a,19 
was mainly restricted to lamina propria cells. This is in line with the 
gene expression data from microdissected colonic epithelial lining 
[Figure 2A]. The IEC localisation and increased expression of ISG15 
in active UC and CD were confirmed by ISH examining ISG15 
mRNA [Figure 2E].
Since ISG15 can enhance IL12-induced IFNγ release14,17,18 and 
IFNγ is upregulated in mucosa during active IBD,9 we analysed 
correlation between expression of ISG15, IFNγ, and the LFA-1 
receptor units ITGAL and ITGB2 in mucosa from non-IBD con-
trols [n = 20] and inactive [n = 65] and active IBD [n = 49]. We 
found a significant correlation between ISG15 and IFNγ mRNA 
expression in inactive [r = 0.34, p = 0.0064] and active [r = 0.5, 
p  <0.0001] IBD that was not observed in controls [r  =  0.17, 
p  =  0.463] [Figure  2F]. Expression of ISG15 mRNA correlated 
strongly with both ITGAL [Figure 2G] and ITGB2 [Figure 2H] 
mRNA when analysing all individuals [n = 134]. Overall, this in-
dicated a possible correlation between ISG15 expression in IECs, 
expression of LFA-1 in immune cells, and enhanced expression of 
IFNγ in mucosa during active IBD.
3.2.  Poly[I:C] and TNF activate type I IFN signalling 
pathway and successive regulation of ISG15 in 
HT29 human intestinal epithelial cells
To investigate whether innate immunity and IEC-specific PRR-
signalling could contribute to type I  IFN signalling pathway and 
regulation of ISG15 in IECs during IBD, we first performed a tran-
scriptome time-series screen in colonic epithelial HT29 cells treated 
with TLR1-9 ligands, NOD2-ligand, IL10, IL1β, or TNF. HT29 
cells showed strongest response to TNF, IL1β, poly[I:C] [TLR3], 
flagellin [TLR5], and LPS [TLR4], as demonstrated by induction 
of mRNAs coding for the IBD-related chemokines CXCL8 and 
CXCL10 [Supplementary Figure 1A, available as Supplementary 
data at ECCO-JCC online]. Gene enrichment analysis revealed that 
TNF, IL1β, and the TLR3 ligand poly[I:C] elicited canonical type 
I IFN signature genes that encode antiviral and inflammatory medi-
ators32,35 [Supplementary Figure 1B and Supplementary File 3]. Both 
regulatory and effector ISGs33 were significantly induced by the three 
ligands compared with untreated controls [Figure 3A].
We then continued to examine regulation of ISG15 protein ex-
pression by TNF, poly[I:C], and IL1β in HT29 cells. Western blot 
analysis confirmed phosphorylation of STAT1 and expression of 
IRF9 and intracellular free ISG15 protein in poly[I:C], IL1β, and 
TNF-treated HT29 cells, as well as after treatment with the known 
IFNAR ligand IFNβ used as positive control [Figure  3B]. We de-
tected significantly enhanced levels of intracellular free ISG15 in the 
ligand-treated cells at 24 h [Figure 3C]. ISG15 conjugates [ISGylated 
proteins] were not observed [Supplementary Figure 2, available as 
Supplementary data at ECCO-JCC online]. Poly[I:C] induced a sig-
nificant release of free ISG15 [Figure 3D].
To test whether poly[I:C] and TNF induced an autocrine/para-
crine JAK1-STAT signalling loop, we pre-treated the cells with the 
JAK1 inhibitor filgotinib or the JAK1/JAK2 inhibitor ruxolitinib 
[Figure 3E] and measured expression of pSTAT1, total STAT, IRF9, 
and ISG15 at 24 h. The levels of all proteins, including intracellular 
and secreted free ISG15, were strongly impaired after pharma-
cologically blocking the JAK-STAT pathway, indicating that the 
signalling went through JAK1. We also detected small amounts of 
poly[I:C]-induced IFNβ in up-concentrated medium [1:5], which 
was again reduced by JAK inhibition [Figure  3E]. When we pre-
treated the cells with neutralising antibody against IFNβ 1 h before 
ligand stimulation, the levels of pSTAT1, IRF9, and free ISG15 in 
TNF- and IFNβ-treated cells were almost similar to untreated con-
trols [Figure  3F–G], indicating that the signalling went through 
IFNAR/JAK, as illustrated in Supplementary Figure 1D. In poly[I:C] 
treated cells, densitometric analysis of intracellular expression of free 
ISG15 protein, and detection of free ISG15 in conditioned medium 
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by ELISA, showed that the response was only partly impaired by 
neutralising antibody against IFNβ versus IgG isotype control 
[Figure 3G–H]. This is in line with other in vitro studies showing 
that some poly[I:C]-induced antiviral genes, including CXCL10 and 
ISG15, can be activated directly by TLR3-signalling, as well as by 
autocrine IFNβ-signalling.36,37 Overall, our results showed that extra-
cellular TNF and poly[I:C] activated type I IFN-signalling through 
JAK1-pSTAT-IRF9 with successive induction of both intracellular 
and secreted free ISG15 in HT29 cells. In addition, free ISG15 can 
be induced by IFN-independent signalling.
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Figure 1. Type I IFN-stimulated genes [ISGs] in whole colonic mucosal pinch biopsies from non-IBD controls [NC], and inactive [i] or active [a] ulcerative colitis 
[UC] and Crohn’s disease [CD]. Microarray-derived mRNA expression levels are shown as log2 signal intensities [Y-axis]. The panels show mean and individual 
values for each gene in the different groups. Active UC [n = 37] versus NC [n = 20] and active CD [n = 7] versus NC [n = 20]: adjusted p-values *<0.05. Active UC 
[n = 37] versus inactive UC [n = 44] and active CD [n = 7] versus inactive CD [n = 19]: adjusted p-values #<0.05 or [#]p <0.2. Differential gene expression analysis 
was performed as described in the Methods section 2.9; p-values were adjusted for multiple comparisons using the Benjamini-Hochberg false-discovery rate 
correction [FDR]. The selected gene expression data are shown in Supplementary File 1, available as Supplementary data at ECCO-JCC online. IBD, inflammatory 
bowel disease; UC, ulcerative colitis; CD, Crohn’s disease.
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Figure 2. Expression of ISGs in colonic epithelium during active IBD. [A] RNASeq data of ISGs in laser-captured, microdissected epithelial monolayer [n = 29]. 
Heat map shows log2 ratios of gene expression in microdissected epithelial cells from inflamed, active IBD [n = 12] compared with expression in epithelial cells 
from uninflamed IBD and normal controls [n = 17]. Differential gene expression analysis was performed as described in the Methods section 2.9; *adjusted 
p-values <0.05. The gene lists are shown in Supplementary File 2, available as Supplementary data at ECCO-JCC online. [B–E] Expression of pSTAT, CD11a, and 
ISG15 [brown] in colonic mucosa from active UC and CD compared with non-IBD control [representative pictures from n = 3–4 in each group]. Insets show higher 
magnification of areas as indicated. Scale bars 100 µm in [B–D], 50 µm in [E]. IHC showing that in active IBD there are [B] increased expression of pSTAT1 in 
both epithelial cells and immune cells infiltrating the lamina propria, [C] infiltration of CD11a [gene name ITGAL] expressing immune cells in in the full depth of 
lamina propria, and [D] increased expression of ISG15 in particularly the surface epithelium. [E] ISH of ISG15 mRNA confirming increased expression in colonic 
epithelial cells during active IBD. [F–H] Scatter plot and Spearman rank correlation analysis of ISG15 mRNA expression versus IFNγ [F], ITGAL [G], and ITGB2 
[H] mRNA expression in colonic pinch biopsies from individual non-IBD controls [NC] [n = 20], inactive IBDi [n = 65] and active IBDa [n = 49] [total n = 134]. IBD, 
inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; IHC, immunohistochemistry; ISH, in situ hybridisation.
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Figure 3. Extracellular signals induce expression of ISGs in HT29 human intestinal epithelial cells. [A] Temporal expression of induced regulatory [upper panel] 
and effector [lower panel] ISGs after TNF [100 ng/ml], IL1β [100 ng/ml], or poly[I:C] [5 µg/ml] treatment. Data shown: pool of triplicate wells. Statistical analysis 
was performed on temporal profiles as described in the Methods section 2.9. Independent validation of TNF [n = 3] and poly[I:C] [n = 5] gene expression at 
6 h are shown in Supplementary Figure 1 and Supplementary File 3, available as Supplementary data at ECCO-JCC online. [B] pSTAT1, total STAT1, IRF9, and 
ISG15 in whole-cell lysates of cells treated with poly[I:C] [5 µg/ml], IL1β [100 ng/ml], or TNF [100 ng/ml] for 1, 6, and 24 h were analysed by western blots. [C] 
Densitometric analysis of intracellular free ISG15 at 1 h, 6 h [n = 2–3], and 24 h [n = 5–8]. [D] Extracellular free ISG15 in conditioned medium detected by ELISA 
[n = 4–5]. [E] Effect of 10 µM filgotinib [JAK1 inhibitor] or 10 µM ruxolitinib [JAK1/JAK2 inhibitor] on intracellular levels of pSTAT1, total STAT, IRF9, and ISG15, 
24 h after treatment with IFNβ [10 ng/ml], poly[I:C] [5 µg/ml], or TNF [100 ng/ml]. Extracellular ISG15 and IFNβ were detected in up-concentrated conditioned 
medium [1:5]. [F] Analysis of autocrine IFNβ signalling. Cells were pre-treated for 1 h with IFNβ-specific neutralising antibody [anti-hIFNβ, 2.5 µg/ml] or isotype 
control [rabbit IgG, 2.5 µg/ml] before treatment with IFNβ, poly[I:C], or TNF. Levels of pSTAT, IRF9, and ISG15 in whole-cell lysate were measured at 24 h. [G] 
Densitometric analysis of the levels of intracellular free ISG15 at 24 h. [H] Extracellular free ISG15 [mean pg/ml + SD] in conditioned medium detected by ELISA; 
p-values were calculated with one-way ANOVA followed by Dunnett’s multiple comparisons test. Each bar in [C] and [G] represents the mean expression ratio 
of ISG15 in ligand-treated cells relative to the reference value of 1 [dotted line] subsequent to normalisation against β-tubulin [loading control]; p-values for 
each treatment group were calculated on log2 transformed values with one-way ANOVA followed by Dunnett’s multiple comparisons test [in C] and by two-way 
ANOVA followed by Šídák [IgG versus abIFNβ] or Tukey [between ligands] multiple comparison test [in G]. Uncropped blot images are shown in Supplementary 
Figure 2, available as Supplementary data at ECCO-JCC online; *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. ELISA, enzyme-linked immunosorbent assay; 
SD, standard deviation; ANOVA, analysis of variance.
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3.3.  Human 3D colonoids release free ISG15 upon 
extracellular stimulation
To examine if poly[I:C] and TNF also could induce type I  IFN 
signature genes in a more physiologically relevant model, we per-
formed additional experiments in primary human 3D colonoids es-
tablished from colonoscopic pinch biopsies.26 The colonoids were 
expanded and differentiated into 3D multicellular structures con-
taining absorptive, goblet, and enteroendocrine cells [Figure  4A]. 
After having established that the human colonoids were responsive 
to poly[I:C] and TNF treatment [Supplementary Figure 3A, avail-
able as Supplementary data at ECCO-JCC online], duplicate RNA 
samples from colonoids treated with poly[I:C] or TNF for 1, 6, and 
24  h were analysed by whole transcriptomic shotgun sequencing 
[RNASeq]. MetaCoreTM pathway enrichment analysis revealed that 
mainly the TLR3 ligand poly[I:C] elicited prototypical type I  IFN 
signature genes in colonoids [Supplementary Figure 3B]. Whereas 
TNF induced fewer ISG mRNAs in human colonoids than in the cell 
line HT29 [Supplementary File  4], several ISGs, including ISG15, 
were significantly upregulated in colonoids treated with poly[I:C] for 
6 and 24 h [Figure 4B].
We then examined whether ISG15 protein expression was en-
hanced in the colonoids after extracellular stimulation. IHC staining 
showed varying intensities of both nuclear [ISGylation] and cyto-
plasmic ISG15 expression in poly[I:C]-, poly[I:C] + TNF-, and IFNβ-
treated colonoids at 24 h [Figure 4C]. ISG15 seems to be expressed 
in both goblet cells and absorptive cells.
Western blot analysis showed that poly[I:C] induced pSTAT1, 
IRF9, and free ISG15 proteins [Figure 4D–E], but with different 
time-dependent expression compared with the positive control: 
In IFNβ-treated cells, pSTAT was detected at as early as 10 min 
[Figure 4D], wheres a similar level of pSTAT was not detected until 
3–6 h after poly[I:C] treatment [Figure 4E]. Organoids pre-treated 
with neutralising antibodies against IFNβ before IFNβ treatment 
had reduced levels of pSTAT1, total STAT1, IRF9, and intracellular 
and secreted free ISG15 at 24  h [Figure  4F]. Levels of the same 
proteins were not impaired in colonoids pre-treated with antibody 
against IFNβ before poly[I:C] treatment [Figure 4F]; and we were 
not able to detect poly[I:C]-induced regulation of IFNβ mRNA in 
colonoids. This indicated that poly[I:C] can induce ISG15 inde-
pendently of an autocrine/paracrine type I IFN signalling loop in 
both primary human IECs and HT29 cells. In line with the observed 
nuclear staining of ISG15 by IHC [Figure 4C], IFNβ and poly[I:C] 
induced ISGylation as well as intracellular and secreted free forms 
of ISG15 in human colonoids [Figure  4F–H and Supplementary 
Figure 4, available as Supplementary data at ECCO-JCC online]. 
Interestingly, only intracellular and secreted free ISG15 were ob-
served in HT29 cells [Supplementary Figure 2]. Densitometric ana-
lysis of western blots of whole-cell lysates showed that although 
TNF induced only minor expression of intracellular free ISG15 
protein at 24  h, we observed a variable, but significant expres-
sion of free ISG15 in poly[I:C]-treated colonoids, and a robust and 
relatively high expression of free ISG15 in IFNβ-treated colonoids 
[Figure 4G]. ELISA analysis showed that free ISG15 was released 
to the medium after treatment with TNF and poly[I:C] as well as 
IFNβ [Figure 4H].
Overall, RNASeq-data, IHC, and western blot analysis showed 
that the type I IFN gene signature and ISG15 protein expression ob-
served in human mucosal biopsies [Figures 1 and 2] were mimicked 
in human epithelial 3D colonoids [Figure 4] which are devoid of any 
immune cells. We also demonstrated that ISG15 can be secreted from 
primary IECs after extracellular stimulation.
3.4.  Correlation between expression of the LFA-1 
receptor unit ITGAL and ISG15-regulated release of 
IFNγ from PBMCs
Since IL12 and IFNγ, as well as the LFA-1 receptor unit CD11a 
[ITGAL], are well-known IBD susceptibility genes,38,39 it was of 
interest to analyse if extracellular ISG15 could modulate IL12-
induced release of IFNγ in immune cells from IBD patients. We first 
confirmed14,19 that extracellular ISG15 and IL12 reproducibly and 
synergistically stimulate release of IFNγ in PBMCs derived from 
three healthy donors [Figure  5A]. We then proceeded to measure 
IFNγ release from PBMCs isolated from non-IBD controls [n = 6], 
inactive IBD patients [n = 16] and active IBD patients [n = 13] after 
treatment with ISG15, IL12, or ISG15 + IL12 combined. Whereas 
PBMCs from both non-IBD controls and IBD patients showed almost 
undetectable basal and ISG15-induced levels of IFNγ release into 
media, IL12 induced variable release of IFNγ from PBMCs derived 
from different individuals, ranging 67–10.500 pg/ml [Supplementary 
Figure 5, available as Supplementary data at ECCO-JCC online]. 
Although we observed great inter-individual differences in sensitivity 
to IL12 and ISG15 treatment within all groups, 83% and 55% of 
PBMC cultures from non-IBD controls and IBD patients, respect-
ively, showed enhanced IFNγ release after ISG15 + IL12 treatment 
compared with IL12 alone [Figure 5B].
It has been reported that IFNγ is released mainly from natural 
killer [NK] cells and T cells upon presence of ISG15 and IL-12, 
although unsorted PBMCs respond better to ISG15  +  IL12 than 
fractioned primary NK or T cells.14 We therefore examined whether 
the variations in synergistic release of IFNγ was due to the relative 
frequency of PBMC subpopulations present in the individual sam-
ples, using flow-cytometric analysis.25 However, we did not find 
any correlation between IFNγ release in response to IL12 + ISG15 
versus IL12 alone and frequency of CD16+ NK-cells or other PBMC 
subpopulations [CD4+, CD8+, CD19+, and CD14+] in PBMCs 
[Figure 5C].
We then examined for a possible correlation between ISG15-
modulated secretion of IFNγ and expression of LFA-1 subunits 
in the cells. Expression levels of ITGAL and ITGB2 [Figure  5D] 
mRNAs in PBMCs derived from the same sample population used in 
the stimulation experiments shown in Figure 5B were quantified by 
RT-qPCR. The expression of both subunits was mostly equal in the 
different groups. When we linked expression levels of ITGAL and 
ITGB2 mRNAs with release of IFNγ from matching PBMC sam-
ples after treatment with IL12+ISG15 versus IL12 alone, we found 
a significant correlation between ITGAL expressions in PBMCs and 
IFNγ concentrations in culture media [r = 0.39, p = 0.02] [Figure 5E].
3.5.  ISG15 boosts release of several IBD-related 
cytokines from PBMCs
To investigate whether ISG15 could regulate secretion of additional 
IBD-related cytokines, PBMCs from three healthy donors were 
treated with recombinant human ISG15, IL12, or IL12  +  ISG15 
combined for 48  h, and secreted cytokines were detected by the 
Bio-Plex Pro Human Chemokine Panel featuring 40 magnetic bead-
based immunoassays. Consistent with findings by others,14,19,20 
IL12 + ISG15 combined elicited a strongly synergistic effect on the 
secretion of IFNγ, and ISG15 alone induced IL6 [Figure  6A] and 
IL10 [Supplementary Figure 6, available as Supplementary data at 
ECCO-JCC online]. Additionally, we found that IL12 alone induced 
strong release of CXCL9 and CXL10, and that ISG15 appeared to 
be a very potent modulator for several other IBD-related cytokines 
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Figure 4. Induction of type I IFN pathway in human colonoids. [A] Colonoids were established from non-IBD control colon crypts, passaged and differentiated from 
Day 10 into multi-cell 3D structures containing central lumen and polarised cells of the major colonic cell types, as indicated. [B] Heatmap showing log2 ratio of ISGs 
in colonoids treated with poly[I:C] for 1, 6, and 24 h versus untreated controls at each time point. Separately independent experiments shown were run in duplicates 
with pools of at least 8 wells. Transcriptome data for poly[I:C]- and TNF-treated colonoids, including MetaCoreTM pathway map, are shown in Supplementary File 4, 
available as Supplementary data at ECCO-JCC online. [C] IHC showing expression of ISG15 protein [brown] in differentiated epithelial cells in colonoids [Day 15] 
treated with the indicated ligands for 24 h [representative pictures from n = at least 5 for each condition]. Scale bars 50 µm. [D–E] Western blot analysis of pSTAT1, 
total STAT1, IRF9, and ISG15 in whole-cell lysates of colonoids treated with IFNβ [20 ng/ml] or poly[I:C] [25 µg/ml] for 10 min, 1 h, 3 h, 6 h, and 24 h. Untreated controls 
at T0 and T24 were loaded in the first and last wells, respectively. [F] Analysis of autocrine IFNβ signalling using IFNβ-specific neutralising antibody [anti-hIFNβ, 2.5 µg/
ml] or isotype control [rabbit IgG, 2.5 µg/ml] 1 h before treatment with IFNβ [20 ng/ml] or poly[I:C] [25 µg/ml]. Levels of pSTAT, total STAT1, IRF9, ISGylation, and free 
ISG15 in whole-cell lysate were measured at 24 h. [G] Densitometric analysis of intracellular free ISG15 at 24 h in TNF- [0.2–0.4 µg/ml, n = 4], poly[I:C]- [10–50 µg/ml, 
n = 6], and IFNβ- [10–20 ng/ml, n = 5] treated colonoids; p-values were calculated as in Figure 3C and G. [H] Detection of free ISG15 in conditioned medium from 
untreated and treated colonoids detected by ELISA [mean + SD; individual experiments indicated by dots]; p-values were calculated with one-way ANOVA followed 
by Dunnett’s multiple comparisons test on log2 transformed data. Uncropped blot images are shown in Supplementary Figure 4, available as Supplementary data 
at ECCO-JCC online; *p <0.05, **p <0.01, ***p <0.001, **** p <0.0001 treated versus untreated controls or as indicated. IBD, inflammatory bowel disease; IHC, 
immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; ANOVA, analysis of variance.
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[Figure 6A, Supplementary Figure 6]. Using a relatively strict selec-
tion criterion as described in the Methods section, the 40-plex ana-
lysis indicated that ISG15 modulated release of CXCL1, CXCL2, 
CXCL5, CCL1, CCL3, CCL7, CCL8, CCL20, CCL25, IL1β, IL6, 
and TNF. In addition, high levels of CXCL8 [out of range] were 
observed [Supplementary Figure 6]. Robust ISG15- and/or IL12-
induced secretion of TNF, CCL20, CXCL8, and CXCL10 was 
confirmed by ELISA analysis of conditioned media from 4–5 inde-
pendent experiments performed on PBMCs from three other healthy 
donors [Figure  6B]. Overall, these results suggest that ISG15 can 
potentiate the release of IBD-related cytokines.
4.  Discussion
In this study we show an increased expression of type I IFN-related 
ISGs in colon epithelium from patients with active IBD. The group 
of ISGs found to be upregulated during active disease is included in 
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Figure 5. ISG15 and IL12 regulate IFNγ release from PBMCs. [A] IFNγ release from PBMCs was detected by ELISA after treatment with ISG15 [500 ng/ml], IL12 
[20 ng/ml], or ISG15 + IL12 [500 + 20 ng/ml] for 48 h. The plot shows mean + SD IFNγ release from three healthy donors with independent experiments marked 
as dots [n = 4]. [B] ISG15-regulated enhanced release of IFNγ from PBMCs isolated from non-IBD controls [n = 6], inactive IBD [n = 16], and active IBD [n = 13]. 
The plot shows ratio IFNγ release [mean + SEM] between ISG15 + IL12 and IL12 alone in the three groups, with individuals indicated by dots. [C] No significant 
correlation between PBMC subpopulations and ratio IFNγ release from PBMCs after treatment with IL12  + ISG15 versus IL12 alone. The plot show PBMC 
subpopulations in 35 samples [Sample set II]. FOP: frequency of parental, CD4+ [T helper cells, monocytes, macrophages, dendritic cells], CD8+ [cytotoxic T 
cells], CD16+ [natural killer cells, monocytes, and macrophages], CD19+ [B cells], CD14+ [co-receptor, PRR]. [D] Expression of ISG15 receptor units,19 ITGAL and 
ITGB2 mRNAs in PBMCs from non-IBD controls [n = 7], inactive IBD [n = 17], and active IBD [n = 15] quantified by RT-qPCR. Fold changes were calculated using 
the ΔΔCT method, where individual expression levels were determined relative to the mean of reference genes and further relative to the mean in the healthy 
non-IBD control group. The figures show mean expression +SD and individual fold changes determined relative to the reference gene [beta actin] for each group. 
[E] Correlation between fold change levels of ISG15 receptor units [ITGB2 and ITGAL] mRNAs and ratio IFNγ release from PBMCs after treatment with IL12 + 
ISG15 versus IL12 alone. Pearson correlation coefficients and p-values are shown; p-values for each group in A and D were calculated with one-way ANOVA 
followed by Dunnett’s multiple comparison test; *p <0.05, **** p <0.0001. IBD, inflammatory bowel disease; PMBC, peripheral blood mononuclear cells; ELISA, 
enzyme-linked immunosorbent assay; SD, standard deviation; SEM, standard error of the mean; ANOVA, analysis of variance; PRR, pattern recognition receptor; 
RT-qPCR, real-time quantitative polymerase chain reaction.
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Figure 6. ISG15 regulates release of IBD-related cytokines from human immune cells. [A] Cytokine profile in conditioned medium from PBMCs treated with ISG15 [500 ng/
ml], IL12 [20 ng/ml], or ISG15 + IL12 [500 + 20 ng/ml] for 48 h and analysed by Human Chemokine Panel featuring 40 magnetic bead-based immunoassays. [A] The plots show 
cytokines [pg/ml] significantly regulated by IL12, ISG15, or combination of both, in PBMCs derived from three healthy donors. All data are shown in Supplementary Figure 6, 
available as Supplementary data at ECCO-JCC online. [B] Validation of multiplex-data by ELISA. The panels show results from independent experiments with PBMCs derived 
from three other healthy donors. The bars show mean cytokine level [pg/ml] + SD in conditioned medium, n = 4–5, indicated by dots. In [A] p-values were calculated by 
two-way ANOVA followed by Tukey’s multiple comparisons test [40 cytokines with six comparisons per cytokine]. In [B], p-values for each donor were calculated with one-
way ANOVA followed by Dunnett’s multiple comparisons test on log2 transformed data; *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. IBD, inflammatory bowel disease; 
PMBCs, peripheral blood mononuclear cells; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; ANOVA, analysis of variance.
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that Mostafavi et al.33 defined as sensitive to tonic type I  IFN sig-
nals at baseline. We did not detect enhanced IFNβ mRNA in colonic 
mucosa during active IBD, but the overall mRNA abundance for 
IFNβ mRNA is minute and close to the lower end of the dynamic 
range of the gene expression assay used. The problem of measuring 
IFNβ regulation directly is well known and has been encountered in 
previous studies,40 and IFNβ is found distributed in epithelium and 
lamina propria in human colonic tissue.41 Although we, like others, 
were unable to show that IFNβ gene expression is regulated during 
inflammation, the transcriptional pattern observed in active IBD is 
consistent with a robust interferon response.
In humans, the impact of type I IFN signalling is reported to be 
both pro-and anti-inflammatory.7,40,42 Slight alterations in the type 
I  IFN signalling network may contribute to imbalanced immune 
responses in IBD,7 but the role of type I  IFNs and ISGs in IECs 
during IBD in the human has not been thoroughly investigated. 
It has been suggested that constitutive type I  IFN signalling in-
duced by the microbiota modulates homeostatic balance through 
tonic signalling in a cell- and context-dependent manner.34,43 Low 
constitutive amounts of IFNβ in the absence of acute infections 
can prime cells in mucosa for strong responses to cytokines, prob-
ably through steady-state abundance of components in the ISGF3 
complex [STAT1, STAT2, and IRF9].34 It was therefore of interest 
to examine if innate immunity could regulate expression of the 
ISGs observed in active IBD through PRR-signalling. By com-
bining examination of human colon biopsies with transcriptomic 
analysis, and studies in a human colon cell line and in primary 
human 3D multicellular colonoids, we show that especially the 
TLR3-ligand poly[I:C] induces a type I IFN response in IECs, with 
enhanced expression of pSTAT1, IRF9, and ISG15 proteins. TLR3 
senses endogenous dsRNA from damaged tissues as well as RNA 
from virus,44 and emerging evidence indicates TLR3-signalling as 
a major factor in homeostasis and wound repair.45 Extracellular 
poly[I:C]-induced expression and secretion of free ISG15 seemed 
to be partly independent of an IFNβ autocrine/paracrine loop, es-
pecially in human colonoids, signifying a possible mechanism for 
endogenous DAMP-induced inflammation in IBD.
Although we observed enhanced levels of ISG15 in conditioned 
medium from both HT29 cells and human colonoids after treat-
ment with poly[I:C], TNF, and the positive control IFNβ, there were 
some differences between the responses in primary IECs and the cell 
line. TNF induced stronger type I IFN signature genes in HT29 cells 
than in human colonoids; and IFNβ and poly[I:C] induced both 
free ISG15 and ISGylation in colonoids, whereas only free ISG15 
was observed in HT29 cells. Examination of fibroblasts from con-
trols and individuals with ISG15 deficiency has shown that human 
intracellular ISG15 can prevent IFNα/β over-amplification and auto-
inflammation.46 In further studies, it would therefore be interesting 
to investigate the impact of ISG15 as an intracellular regulator of 
aberrant expression of type I IFNs and ISGs in human primary IECs.
In the present study, we focused on regulation and 
immunomodulatory effects of extracellular free ISG15. We show for 
the first time that ISG15 can be released from primary human IECs 
upon external stimulation, and that extracellular ISG15 can regu-
late release of several IBD-related cytokines from PBMCs. Although 
the cytokine responses in PBMCs seemed reproducible within the 
six healthy donors examined, we observed large inter-individual 
variation in IFNγ release from ISG15- and IL12-treated PBMCs 
derived from non-IBD controls and IBD patients. We found that 
ISG15-modulated secretion of IFNγ correlated weakly, but signifi-
cantly with mRNA expression levels of the LFA-1 integrin receptor 
unit CD11a [ITGAL] in PBMCs. The LFA-1 integrin receptor is ex-
pressed on T cells, B cells, macrophages, neutrophils, and NK cells.47 
In the context of IBD, LFA-1 on T cells is best known as receptor for 
ICAM1. Swaim et  al. 201719 showed that extracellular ISG15 in-
duces IFNγ and IL10 secretion through the LFA-1 integrin receptor 
in an NK-92 cell line-based assay and in CD11a KO mice, but no 
data regarding ISG15 receptors on human primary cells are pub-
lished. Our transcriptome data from human colon biopsies indicated 
a correlation between ISG15 and ITGAL expression and enhanced 
expression of IFNγ in colon mucosa during active IBD. Whereas 
more investigation is needed to address ISG15 receptors on human 
primary immune cells, we propose a model based on our data and 
literature12,19 where dsRNA[TLR3], PAMPs, or DAMPs signalling 
and induced ISGs contribute to inflammation in active IBD by, for 
example, enhanced expression of IEC-derived free ISG15. The se-
creted free form of human ISG15 can boost IBD-relevant immune 
activities, including chemotaxis of neutrophils15 and regulation of 
cytokines such as IFNγ, CXCL1, CXCL5, CXCL8, CCL20, TNF, 
IL6, and IL1β released from infiltrating immune cells [Supplementary 
Figure 7, available as Supplementary data at ECCO-JCC online]. 
To date, around 240 single nucleotide polymorphisms [SNPs] as-
sociated with increased IBD risk have been identified, comprising 
genes related to intestinal epithelial function, as well as innate and 
adaptive immune responses.38,39,48,49 Central genes in the IFNAR1-
STAT1-ITGAL-ISG15-cytokine network are associated with IBD-
related genetic polymorphisms [SNPs],38,39,48 such as IFNAR1 
[rs2284553], STAT1 [rs1517352], IRF1 [rs2188962], IL12B 
[rs6871626], IFNγ [rs7134599], ITGAL [rs11150589], the major 
ligand for LFA-1 on T-cells: ICAM1 [rs5498], IL12B [rs6871626], 
CCL20 [rs11178120348_ rs181171139], and the chemokines CXCL1, 
CXCL5, and CXCL8 [all rs2472649].
D’Cunha et  al.50 showed already in 1996 that administra-
tion of IFNβ to healthy individuals increased serum ISG15 levels 
significantly, and suggested that free ISG15 may represent an im-
portant mediator of the host response to IFNα/β by amplifying the 
immunomodulatory effects of IFNs. ISG15 has later been suggested 
as biomarker and/or target for treatment in human diseases such 
as systemic lupus erythematosus,51 active tuberculosis,20 oesopha-
geal squamous cell carcinoma,52 and pancreatic cancer.53 Treatment 
with IFNβ in IBD has shown contradictory results,7 but inhibition 
of the JAK-STAT pathway represents a promising therapeutic target 
for moderate to severe UC.54 However, JAK proteins can bind to 
various types of cytokine receptor families55; and the overall effect of 
JAK inhibitors can be difficult to predict in humans. We argue that 
a better understanding of cell- and context-dependent activation of 
type I  IFN signalling and expression of ISGs in human intestinal 
mucosa can identify effector ISGs to be targeted in IBD treatment, 
hopefully without the side effects following treatments directed at 
broader upstream signalling components such as IFNβ and/or JAK1-
STAT. Here we showed that ISG15 can modulate release of a variety 
of IBD-related cytokines and is therefore an intriguing candidate for 
immunotherapy in IBD.
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